83 related articles for article (PubMed ID: 3052829)
1. Correlation between tumor proliferation and serum levels of beta 2-microglobulin and thymidine kinase in malignant lymphomas.
Lehtinen T
Cancer Detect Prev; 1988; 12(1-6):125-31. PubMed ID: 3052829
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of serum thymidine kinase and beta 2 microglobulin in subjects affected by multiple myeloma.
Musolino C; Allegra A; Orlando A; Grosso P; Alonci A; Cincotta M; Squadrito G
Riv Eur Sci Med Farmacol; 1990; 12(4-5):233-8. PubMed ID: 2103961
[TBL] [Abstract][Full Text] [Related]
3. Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma.
Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3025-9. PubMed ID: 9329592
[TBL] [Abstract][Full Text] [Related]
4. [Beta 2 microglobulin in serum--a "tumor marker" in malignant lymphomas?].
Aulbert E; Steffens O
Med Klin (Munich); 1990 Jan; 85(1):13-7. PubMed ID: 2179698
[TBL] [Abstract][Full Text] [Related]
5. Circadian variations of interleukin-2 receptors, serum thymidine kinase and beta-2-microglobulin in patients with non-Hodgkin's lymphoma and normal controls.
Micke O; Schäfer U; Wörmann B; Hiddemann W; Willich N
Anticancer Res; 1997; 17(4B):3007-10. PubMed ID: 9329587
[TBL] [Abstract][Full Text] [Related]
6. Flow cytometric S-phase fraction as a complementary biological parameter for the cytological grading of non-Hodgkin's lymphoma.
Pinto AE; Cabeçadas J; Nóbrega SD; Mendonça E
Diagn Cytopathol; 2003 Oct; 29(4):194-9. PubMed ID: 14506670
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of DNA ploidy pattern, S-phase fraction (SPF), and proliferating cell nuclear antigen (PCNA) in patients with primary gastric lymphoma.
Belessi CJ; Parasi AS; Manioudaki HS; Laoutaris NP; Legakis NC; Peros GT; Androulakis GA
J Surg Oncol; 2003 Apr; 82(4):247-55. PubMed ID: 12672009
[TBL] [Abstract][Full Text] [Related]
8. Serum thymidine kinase and soluble interleukin-2 receptor predict recurrence of malignant lymphoma.
Wakao D; Murohashi I; Tominaga K; Yoshida K; Kishimoto K; Yagasaki F; Itoh Y; Itoh K; Sakata T; Kawai N; Kayano H; Suzuki T; Matsuda A; Hirashima K; Bessho M
Ann Hematol; 2002 Mar; 81(3):140-6. PubMed ID: 11904739
[TBL] [Abstract][Full Text] [Related]
9. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.
Spyratos F; Ferrero-Poüs M; Trassard M; Hacène K; Phillips E; Tubiana-Hulin M; Le Doussal V
Cancer; 2002 Apr; 94(8):2151-9. PubMed ID: 12001111
[TBL] [Abstract][Full Text] [Related]
10. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression.
Matthews C; Catherwood MA; Morris TC; Kettle PJ; Drake MB; Gilmore WS; Alexander HD
Eur J Haematol; 2006 Oct; 77(4):309-17. PubMed ID: 16856923
[TBL] [Abstract][Full Text] [Related]
11. A non-radiometric method for measuring serum thymidine kinase activity in malignant lymphoma in dogs.
von Euler HP; Ohrvik AB; Eriksson SK
Res Vet Sci; 2006 Feb; 80(1):17-24. PubMed ID: 16140350
[TBL] [Abstract][Full Text] [Related]
12. Cell proliferation in ovarian carcinoma: superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate.
Meyer JS; Gersell DJ; Yim S
Gynecol Oncol; 2001 Jun; 81(3):466-76. PubMed ID: 11371140
[TBL] [Abstract][Full Text] [Related]
13. Urinary pseudouridine in patients with lymphoma: comparison with other clinical parameters.
Masaki Y; Itoh K; Sawaki T; Karasawa H; Kawanami T; Fukushima T; Kawabata H; Wano Y; Hirose Y; Suzuki T; Sugai S; Umehara H
Clin Chim Acta; 2006 Sep; 371(1-2):148-51. PubMed ID: 16643879
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of serum neural cell adhesion molecule as a prognostic marker in multiple myeloma.
Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):3021-4. PubMed ID: 9329591
[TBL] [Abstract][Full Text] [Related]
15. Thymidine kinase (TK) activity as a prognostic parameter of survival in lymphoma patients.
Bogni A; Cortinois A; Grasselli G; Seregni E; Crippa F; Castellani MR; Bombardieri E
J Biol Regul Homeost Agents; 1994; 8(4):121-5. PubMed ID: 7660854
[TBL] [Abstract][Full Text] [Related]
16. An in-house assay for serum deoxythymidine kinase.
Seah LH; Ton SH; Cheong SK; Hamidah NH
Malays J Pathol; 1991 Dec; 13(2):109-13. PubMed ID: 1823092
[TBL] [Abstract][Full Text] [Related]
17. [Serum thymidine kinase in multiple myeloma: I. Relation to selected laboratory indicators in the disease].
Scudla V; Bacovský J; Papajík T; Budíková M; Srovnalík K
Vnitr Lek; 1994 Mar; 40(3):151-6. PubMed ID: 8184566
[TBL] [Abstract][Full Text] [Related]
18. GM-CSF raises serum levels of beta 2-microglobulin and thymidine kinase in patients with chronic lymphocytic leukaemia.
Itälä M; Pelliniemi TT; Remes K
Br J Haematol; 1996 Jul; 94(1):129-32. PubMed ID: 8757522
[TBL] [Abstract][Full Text] [Related]
19. Thymidine kinase levels correlate with prognosis in aggressive lymphoma and can discriminate patients with a clinical suspicion of indolent to aggressive transformation.
Gatt ME; Goldschmidt N; Kalichman I; Friedman M; Arronson AC; Barak V
Anticancer Res; 2015 May; 35(5):3019-26. PubMed ID: 25964590
[TBL] [Abstract][Full Text] [Related]
20. [Complex assessment of the proliferation of epidermal and tumor cells in malignant skin lymphoma].
Persina IS; Zabanova EV; Kotel'nikov VM; Kazantseva IA; Averbakh EV
Vestn Dermatol Venerol; 1989; (10):4-7. PubMed ID: 2609746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
